rss
Eur J Hosp Pharm 19:464 doi:10.1136/ejhpharm-2012-000108
  • EMA new drug

Telavancin (Vibativ): a new glycopeptide antibiotic

Telavancin better than vancomycin?

  1. Mark Nolan
  1. Correspondence to
    Mark Nolan, EJHP correspondent; friendofpills{at}me.com

Telavancin has been approved by the European Medicines Agency (EMA) only for hospital-acquired pneumonia (HAP) known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA). It is a glycopeptide antibiotic derivative of vancomycin and like vancomycin only covers gram-positive bacteria. Its mechanism of action includes inhibition of cell wall biosynthesis similar to vancomycin. In addition, it binds to bacterial cell membranes, causing depolarisation of membrane potential and causing an increase in cell membrane permeability. Does that actually translate into a stronger antibiotic? It does not appear so at this time. Telavancin is a bit of a pharmacotherapy nightmare. The reason why it is a nightmare is because it actually works and it has not been shown to be inferior to vancomycin. Why is that a problem? It is a problem because it becomes difficult to say no to providers who want …

EJHP blog

Analysis and discussion of the latest news, research findings and policy developments in hospital pharmacy.

Visit the blog >>

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EJHP.

View free sample issue >>

Email alerts

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article